GleamWall
中文EN

GLUE Monte Rosa Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1826457 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-61.3%
TTM net income YoY-725.3%
TTM EPS YoY-574.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-214.5%
Net margin-186.2%
FCF margin-248.0%
EBITDA margin-202.8%

Returns

ROE-35.3%
ROA-22.6%
ROIC (approx.)-48.8%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets28.9%
Debt / equity0.00x
Current ratio10.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio6.0%
Payout ratio—
Capex / revenue12.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$54.37M$8.97M$4.21M$2.78M$12.77M$23.19M$84.93M$60.65M
R&D expense$45.36M$47.96M$44.07M$41.98M$36.68M$30.65M$32.19M$38.87M
SG&A expense$10.94M$10.13M$10.18M$10.52M$9.06M$8.10M$8.70M$8.78M
Operating income-$1.94M-$49.13M-$50.03M-$49.72M-$32.98M-$15.55M$44.04M$13.00M
Pretax income$3.78M-$43.19M-$44.45M-$46.08M-$30.26M-$11.10M$47.71M$15.60M
Income tax$716,000$208,000$52,000$59,000-$3.18M$1.20M$822,000$2.16M
Net income$3.06M-$43.40M-$44.50M-$46.13M-$27.08M-$12.29M$46.88M$13.44M
EBITDA$205,000-$47.22M-$48.01M-$47.63M-$30.88M-$13.43M$46.08M$15.06M
EPS (diluted)————————
Weighted avg. shares (diluted)108.62M101.48M99.88M—82.40M82.19M82.96M—
Balance sheet
Cash & equivalents$45.18M$90.10M$159.86M$129.88M$208.34M$69.43M$78.53M$229.12M
Current assets$640.07M$631.41M$677.55M$393.19M$401.82M$299.46M$332.28M$377.44M
PP&E, net$28.63M$29.93M$28.41M$25.99M$27.60M$29.05M$29.34M$29.48M
Total assets$697.73M$691.16M$736.43M$448.66M$459.84M$359.59M$393.20M$438.73M
Current liabilities$62.05M$59.66M$71.04M$64.21M$61.44M$41.85M$59.22M$156.95M
Total liabilities$201.52M$203.88M$214.51M$215.60M$214.00M$91.51M$118.04M$215.80M
Shareholders' equity$496.21M$487.28M$521.92M$233.06M$245.84M$268.08M$275.16M$222.94M
Shares outstanding85.43M85.23M84.32M65.54M61.79M61.72M61.51M61.51M
Cash flow statement
Operating cash flow-$40.98M-$44.11M-$37.37M-$43.01M$100.43M-$34.72M-$45.49M$128.92M
Capital expenditure$1.56M$4.72M$1.87M$767,000$651,000$1.70M$1.59M$183,000
Free cash flow-$42.54M-$48.84M-$39.24M-$43.78M$99.78M-$36.41M-$47.08M$128.74M
Investing cash flow-$4.54M-$28.86M-$261.00M-$65.07M$38.14M$25.32M-$100.23M-$30.90M
Financing cash flow$568,000$3.21M$328.33M$29.62M$348,000$365,000$14,000$608,000
Depreciation & amortization$2.14M$1.91M$2.03M$2.09M$2.10M$2.12M$2.05M$2.06M
Stock-based compensation$6.32M$5.97M$5.95M$4.31M$4.36M$4.89M$5.30M$4.47M
Dividends paid$0$0$0$0$0$0$0$0

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.